This Article Full Text Full Text (PDF) Correction (v37,p2444) All Versions of this Article: 37/9/2294    most recent 01.STR.0000236840.00467.84v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lip, G. Y.H. Articles by Hart, R. G. Search for Related Content PubMed PubMed Citation Articles by Lip, G. Y.H. Articles by Hart, R. G. Related Collections Other Stroke Treatment - Medical Thrombosis risk factors

(Stroke. 2006;37:2294.)
© 2006 American Heart Association, Inc.

Original Contributions

Additive Role of Plasma von Willebrand Factor Levels to Clinical Factors for Risk Stratification of Patients With Atrial Fibrillation

Gregory Y.H. Lip, MD; Deirdre Lane, PhD; Carl Van Walraven, MD Robert G. Hart, MD

From the Haemostasis, Thrombosis and Vascular Biology Unit (G.Y.H.L., D.L.), University Department of Medicine, City Hospital, Birmingham, England; Ottawa Health Research Institute (C.V.W.), Ottawa, Canada; and the University of Texas Health Science Center (R.G.H.), San Antonio.

Correspondence to Prof G.Y.H. Lip, Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, England, UK. E-mail g.y.h.lip{at}bham.ac.uk

Background and Purpose— To aid decisions for thromboprophylaxis in atrial fibrillation (AF), several risk stratification schemes that predict stroke risk according to clinical and echocardiographic features have been published. von Willebrand factor (vWf) is a plasma markers of endothelial damage/dysfunction and is associated with the risk of stroke and vascular events in AF patients. This study determined the additive role of plasma vWf levels to clinical factors for risk stratification in patients with AF.

Methods— We classified 994 AF patients who were enrolled in the SPAF III trial as being at low, moderate, or high risk of stroke and thromboembolism according to the Birmingham and CHADS₂ risk stratification schemes. vWf levels were classified as elevated when 158 IU /dL. Rates of ischemic stroke and vascular events within each clinical risk stratum with and without plasma vWf levels were compared.

Results— The accuracy of both clinical risk stratification schemes was similar for predicting event rates (Birmingham: ischemic strokes, 0.642; vascular events, 0.670; CHADS₂: ischemic strokes, 0.672; vascular events, 0.672). Subsequent addition of categorized vWf levels to both clinical risk stratification schemes further refined risk stratification for stroke and vascular events. When added to the Birmingham and CHADS₂ clinical risk stratification, high vWf levels were independently associated with a risk of vascular events (hazard ratio, 2.05; 95% confidence interval, 1.30 to 3.22 and 2.01, 1.27 to 3.18 with Birmingham and CHADS₂, respectively) but not ischemic stroke.

Conclusions— When added to clinical risk stratification schemes (Birmingham; CHADS₂), plasma vWf levels refined clinical risk stratification for stroke and vascular events among AF patients. vWf levels may aid decisions about thromboprophylaxis, particularly among AF patients at moderate risk.

Key Words: atrial fibrillation • cerebrovascular accident • prophylaxis • risk assessment • stroke

This article has been cited by other articles:

				D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]

				Stroke Risk in Atrial Fibrillation Working Group Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation Stroke, June 1, 2008; 39(6): 1901 - 1910. [Abstract] [Full Text] [PDF]

				G. Y.H. Lip The Balance Between Stroke Prevention and Bleeding Risk in Atrial Fibrillation: A Delicate Balance Revisited Stroke, May 1, 2008; 39(5): 1406 - 1408. [Full Text] [PDF]

				M. C. Fang, A. S. Go, Y. Chang, L. Borowsky, N. K. Pomernacki, D. E. Singer, and for the ATRIA Study Group Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation J. Am. Coll. Cardiol., February 26, 2008; 51(8): 810 - 815. [Abstract] [Full Text] [PDF]

				N. Dudley and R. Fuller Comment on the WASPO study Age Ageing, September 1, 2007; 36(5): 598 - 599. [Full Text] [PDF]

				G. Y.H. Lip, J. V. Patel, E. Hughes, and R. G. Hart High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation: Relationship to Stroke Risk Factors, Stroke Risk Stratification Schema, and Prognosis Stroke, April 1, 2007; 38(4): 1229 - 1237. [Abstract] [Full Text] [PDF]

				L Kalra, G Y H Lip, and on behalf of the Guideline Development Group for t Antithrombotic treatment in atrial fibrillation Heart, January 1, 2007; 93(1): 39 - 44. [Full Text] [PDF]

				P. Kakar, D. Lane, and G. Y. H. Lip Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. Chest, November 1, 2006; 130(5): 1296 - 1299. [Full Text] [PDF]